{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:02:01Z","timestamp":1793916121559,"version":"4.8.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myeloid\/lymphoid neoplasm with eosinophilia (MLN-Eo) is a World Health Organization (WHO) established category of hematologic malignancies primarily arising in adults. We discuss an 8-month-old infant who presented with clinical features similar to those of juvenile myelomonocytic leukemia (JMML) but who was diagnosed with MLN-Eo driven by an ETV6-FLT3 fusion. Results of patient-derived leukemia ex vivo studies demonstrated increased sensitivity to type I FLT3 inhibitors as compared with type II inhibitors. Treatment with the type I inhibitor gilteritinib resulted in complete immunophenotypic and cytogenetic remission. This patient subsequently underwent a hematopoietic stem cell transplant and remains in complete remission 1 year later. This is the youngest patient reported with an ETV6-FLT3 fusion and adds to the mounting reports of FLT3-rearranged MLN-Eo, supporting its addition to the WHO classification. Furthermore, this case highlights the clinical utility of ex vivo drug testing of targeted therapies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003699","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T15:56:32Z","timestamp":1617292592000},"page":"1899-1902","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["<i>ETV6-FLT3\u2013<\/i>positive myeloid\/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1603-1381","authenticated-orcid":false,"given":"Barbara","family":"Spitzer","sequence":"first","affiliation":[{"name":"MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, Weill Cornell Medicine, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filemon S.","family":"Dela Cruz","sequence":"additional","affiliation":[{"name":"MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glorymar D.","family":"Ibanez Sanchez","sequence":"additional","affiliation":[{"name":"Sloan Kettering Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hematopathology Service, Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8586-8500","authenticated-orcid":false,"given":"Wenbin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Hematopathology Service, Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryma","family":"Benayed","sequence":"additional","affiliation":[{"name":"Hematopathology Service, Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; and"},{"name":"Department of Dermatology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Irene","family":"Rodriguez-Sanchez","sequence":"additional","affiliation":[{"name":"MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Bouvier","sequence":"additional","affiliation":[{"name":"MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[{"name":"Hematopathology Service, Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Kung","sequence":"additional","affiliation":[{"name":"MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav","family":"Shukla","sequence":"additional","affiliation":[{"name":"MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"issue":"20","key":"2021040115362281000_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2021040115362281000_B2","doi-asserted-by":"crossref","first-page":"a003079","DOI":"10.1101\/mcs.a003079","article-title":"Two myeloid leukemia cases with rare FLT3 fusions","volume":"4","author":"Zhang","year":"2018","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"8","key":"2021040115362281000_B3","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2021040115362281000_B4","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","article-title":"FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation","volume":"20","author":"Vu","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"2021040115362281000_B5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12308-014-0203-6","article-title":"ETV6 \/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia","volume":"7","author":"Hosseini","year":"2014","journal-title":"J Hematop"},{"issue":"10","key":"2021040115362281000_B6","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","article-title":"ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant","volume":"28","author":"Falchi","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"2021040115362281000_B7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00277-013-1843-9","article-title":"Successful allogeneic stem cell transplantation with long-term remission of ETV6\/FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia","volume":"93","author":"Chonabayashi","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"2021040115362281000_B8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.1987.tb02291.x","article-title":"Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: a nonrandom association","volume":"67","author":"Keene","year":"1987","journal-title":"Br J Haematol"},{"key":"2021040115362281000_B9","doi-asserted-by":"crossref","first-page":"106460","DOI":"10.1016\/j.leukres.2020.106460","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia and FLT3 rearrangement","volume":"99","author":"Shao","year":"2020","journal-title":"Leuk Res"},{"issue":"10","key":"2021040115362281000_B10","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/leu.2017.240","article-title":"Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia","volume":"31","author":"Jawhar","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"2021040115362281000_B11","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia [published correction appears in Nat Genet. 2015;47(11):1333]","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"2021040115362281000_B12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41375-019-0549-y","article-title":"Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing","volume":"34","author":"Chao","year":"2020","journal-title":"Leukemia"},{"issue":"14","key":"2021040115362281000_B13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2017-07-798157","article-title":"Integrated molecular profiling of juvenile myelomonocytic leukemia","volume":"131","author":"Murakami","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2021040115362281000_B14","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-03-4026","article-title":"HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2)","volume":"64","author":"Morerio","year":"2004","journal-title":"Cancer Res"},{"key":"2021040115362281000_B15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/asheducation-2018.1.307","article-title":"JMML genomics and decisions","volume":"2018","author":"Niemeyer","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2021040115362281000_B16","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.exphem.2007.07.002","article-title":"A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy","volume":"35","author":"Grand","year":"2007","journal-title":"Exp Hematol"},{"issue":"2","key":"2021040115362281000_B17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/leu.2016.304","article-title":"A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?","volume":"31","author":"Troadec","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"2021040115362281000_B18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"2021040115362281000_B19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2019-129557","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ AML improves event-free survival and reduces relapse risk: a report from the Children\u2019s Oncology Group Protocol AAML1031","volume":"134","author":"Pollard","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2021040115362281000_B20","first-page":"614","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia\/basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition","volume":"106","author":"Yao","year":"2021","journal-title":"Haematologica"},{"issue":"19","key":"2021040115362281000_B21","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/bloodadvances.2019001282","article-title":"Diagnosis and treatment of mixed phenotype (T-myeloid\/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement","volume":"4","author":"Carll","year":"2020","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/1899\/1804134\/advancesadv2020003699.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/7\/1899\/1804134\/advancesadv2020003699.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T15:56:44Z","timestamp":1617292604000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/7\/1899\/475626\/ETV6-FLT3-positive-myeloid-lymphoid-neoplasm-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003699","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]}}}